Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle Roman

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Leukemia Research|December 7, 2010
Preclinical evaluation of potential nilotinib cardiotoxicityArmin Wolf, Philippe Couttet, Min Dong, et al.
Toxicology and Applied Pharmacology|September 1, 2016
Ocular toxicity of AUY922 in pigmented and albino ratsDanielle Roman, James VerHoeve, Heiko Schadt, et al.
Leukemia Research|February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studiesArmin Wolf, Philippe Couttet, Min Dong, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Leukemia Research|December 7, 2010
Preclinical evaluation of potential nilotinib cardiotoxicityArmin Wolf, Philippe Couttet, Min Dong, et al.
Toxicology and Applied Pharmacology|September 1, 2016
Ocular toxicity of AUY922 in pigmented and albino ratsDanielle Roman, James VerHoeve, Heiko Schadt, et al.
Leukemia Research|February 4, 2010
Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studiesArmin Wolf, Philippe Couttet, Min Dong, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Pageof 2